Volume 11 Supplement 1
Screening for hypertrophic cardiomyopathy: a cost analysis of echocardiography, cardiac magnetic resonance and genetic testing
© Hauser et al; licensee BioMed Central Ltd. 2009
Published: 28 January 2009
Hypertrophic cardiomyopathy (HCM) is the most common heritable cardiomyopathy and is the leading cause of sudden cardiac death early in life. Screening of first degree relatives for HCM phenotype is recommended, typically with serial echocardiography (Echo). Recently, cardiovascular magnetic resonance (CMR) and genetic testing (GT) have emerged as additional screening strategies. Up to 5% of patients with HCM on CMR have normal Echo findings. GT has been proposed as a method for eliminating unnecessary diagnostic imaging tests in genotype negative family members in families identified to have a disease causing mutation, present approximately 50% of the time. Because large, long-term trials to compare these methods are not feasible, modeling of costs and outcomes can provide insight into the potential costs and benefits of various screening strategies.
The objective of this study is to evaluate the costs and benefits of screening strategies of HCM using Echo, CMR and GT.
We developed a Markov model to evaluate 5 screening strategies: Echo, CMR, Echo and GT, CMR and GT, and Echo, CMR and GT. All screening strategies were designed based on standard guidelines with first testing at age 13, with imaging with Echo and/or CMR every 2 years until age 25 and every 7 years until age 50. GT was performed once only at the start of screening. The model was tested using a theoretical cohort of 1000 probands with an average of 4 first degree relatives that required testing. The base case assumed an Echo cost of $650, CMR cost of $800, and GT cost of $3000. The penetrance of HCM was modeled such that, of those destined to have HCM, 90% of screened first degree relatives would have phenotypic HCM by age 25 with the remaining 10% evident by age 50. Echo was assumed to have a 5% error rate compared to CMR. The analysis was performed from the societal perspective using constant 2008 dollars. A 3% discount rate was used.
In this model of screening for HCM, GT increased costs without improving outcome. Screening with CMR identified a larger proportion of patients with HCM with an associated increase in cost.
This article is published under license to BioMed Central Ltd.